Alnylam boasts PhII win in kidney disease cornerstone of Regeneron R&D blockbuster deal
A drug at the heart of the $1 billion-plus Alnylam and Regeneron collaboration cemented three years ago has some new efficacy data to show off.
The RNAi biotech once helmed by John Maraganore reported positive topline data Thursday for its investigational cemdisiran, an RNAi drug targeting the C5 component of the pathway that both Alnylam and Regeneron are working on in IgAN, or immunoglobulin A nephropathy. The data come out of a Phase II descriptive trial, with no statistical hypothesis testing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.